Safe, secure blood supply

/Safe, secure blood supply
Safe, secure blood supply2018-06-19T20:34:39+00:00

The CHS advocates for access to a secure supply of the safest and most efficacious therapies for the treatment of inherited bleeding disorders.

Safe, secure blood supply – Report cards

Canadian Blood Services Board appointments

Blood Injury Compensation Scheme

Inhibitor rates related to treatment product in previously untreated patients:Statement from the WFH

Submissions on the funding of extended half‐life factor concentrates

Eloctate™ and Alprolix™, extended half-life factor VIII and factor IX for the treatment of hemophilia A and B, are approved by Health Canada. The Canadian Hemophilia Society submitted its recommendations concerning reimbursement in 2014. In 2016, both Canadian Blood Services and Héma-Québec added the two products to the list of those that could be reimbursed through their blood system budgets.

CHS recommendations re Eloctate

CHS recommendations re Alprolix